Prof. Dr. Michael Joner
Contact:
German Heart Centre Munich
Lazarettstraße 36
80636 München
Email: dobrowolski@dhm.mhn.de
Website: www.dhm.mhn.de
Research areas: atherosclerosis, imaging, vascular intervention
Michael Joner is DZHK Professor for Early Clinical Trials at the German Heart Centre Munich. His main research focus is on findings novel diagnostic or therapeutic pathways to target atherosclerosis.
Research focus
Prof. Joner’s research wants to find new solutions to identify and treat patients at risk for acute cardiovascular events utilizing innovative diagnostic and therapeutic approaches. His group investigates high-risk markers of atherosclerosis derived from human tissue, which is expected to ultimately feed into molecular imaging approaches to specifically detect and treat high-risk atherosclerotic plaques prone to cause cardiovascular events. Prof. Joner utilizes human-relevant animal models to investigate novel imaging catheters and percutaneous interventional procedures and aims to facilitate early clinical trial investigation of these novel approaches. In a separate aim, his group focusses on optimizing procedures for structural heart interventions in a highly translational setting.
Prof. Joner hopes that in the long term, it will be possible to identify patients at risk for cardiovascular events before they become symptomatic with acute myocardial infarction or sudden cardiac death. Furthermore, he aims to find a solution for longer-lasting percutaneous procedures in the field of structural heart interventions.
Prof Michael Joner discusses Magmaris RMS: BIOSOLVE-II OCT post hoc analysis - Implications on neoatherosclerosis at 3 years.
Major achievements and awards
- ESC award for Medical Innovation
- Leducq Grant; Principal Investigator of the Leducq Foundation project: “Defining the Roles of Smooth Muscle Cells and Other Extracellular Matrix Producing Cells in Late-Stage Atherosclerotic Plaque Pathogenesis”
- DZHK – TRP Projekt “A translational approach to improve vascular healing after coronary intervention”
Key publications
Joner M, Koenig W. Risk prediction by non-invasive coronary imaging: we are not there yet! Eur Heart J. 2018 Mar 14;39(11):942-944. doi: 10.1093/eurheartj/ehx801. PubMed PMID: 29340589. Impact Factor: 23.425.
Joner M, Koppara T, Byrne RA, Castellanos MI, Lewerich J, Novotny J, Guagliumi G, Xhepa E, Adriaenssens T, Godschalk TC, Malik N, Alfonso F, Tada T, Neumann FJ, Desmet W, Ten Berg JM, Gershlick AH, Feldman LJ, Massberg S, Kastrati A. Prevention of PRESTIGE Investigators. Neoatherosclerosis in Patients with Coronary Stent Thrombosis: Findings From Optical Coherence Tomography Imaging (A Report of the PRESTIGE Consortium). JACC Cardiovasc Interv. 2018 Jul 23;11(14):1340-1350. doi: 10.1016/j.jcin.2018.02.029. PubMed PMID: 30025727. Impact Factor: 9.881.
Joner M, Xhepa E. Consequences of Vascular Calcification: Implications for Bioresorbable Vascular Scaffolds. JACC Cardiovasc Imaging. 2017 Oct;10(10 PtA):1162-1164. doi: 10.1016/j.jcmg.2016.12.012. Epub 2017 Mar 15. PubMed PMID: 28330667. Impact Factor: 10.247.
Joner M, Koppara T, Virmani R, Byrne RA. Improving vessel healing with fully bioresorbable drug-eluting stents: more than a pipe dream? Eur Heart J. 2015 Oct 15. pii: ehv537. PMID: 26475833. Impact Factor: 15.203
Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008 Jul 29;52(5):333-42. doi: 10.1016/j.jacc.2008.04.030. PMID: 18652940. Impact Factor: 16.503
Joner M, Farb A, Cheng Q, Finn AV, Acampado E, Burke AP, Skorija K, Creighton W, Kolodgie FD, Gold HK, Virmani R. Pioglitazone inhibits in-stent-restenosis in atherosclerotic rabbits by targeting MCP-1 and TGF-beta-1. Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):182-9. Epub 2006 Oct 26. PMID: 17068283. Impact Factor: 14.43
Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006 Jul 4;48(1):193-202. Epub 2006 May 5. PMID: 16814667. Impact Factor: 16.503
Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014 Aug 19;64(7):635-43. doi: 10.1016/j.jacc.2014.03.059. PMID: 25125292. Impact Factor: 16.503
Malle C, Tada T, Steigerwald K, Ughi GJ, Schuster T, Nakano M, Massberg S, Jehle J, Guagliumi G, Kastrati A, Virmani R, Byrne RA, Joner M. Tissue characterization after drug-eluting stent implantation using optical coherence tomography. Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1376-83. doi: 10.1161/ATVBAHA.113.301227. Epub 2013 Mar 28. PMID: 23539216. Impact Factor: 6.0